Gilead Sciences Inc is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases. The company's mission is to advance the care of patients worldwide through groundbreaking research and development. Gilead Sciences Inc employs a strategy focused on leveraging its scientific expertise and robust pipeline to deliver transformative therapies, while also fostering collaborations and partnerships to enhance its operational capabilities and expand access to its life-saving treatments globally.

GILEAD SCIENCES INC

Gilead Sciences, Inc. (GILD) is poised for a significant year ahead as it prepares to launch lenacapavir as a pre-exposure prophylactic for HIV, anticipating FDA approval by mid-2025. During a recent earnings call, Gilead's Chief Commercial Officer indicated robust demand for lenacapavir, noting an increase in HIV doctor appointments. Trials...

Gilead Anticipates Strong Growth with Upcoming Launch of Lenacapavir and Record Sales from Biktarvy as Stock Performance Remains Steady Amid Market Challenges